10-Q: Verrica Pharmaceuticals Reports Strong Revenue, Reduced Losses

Verrica Pharmaceuticals Inc. reported significantly increased revenue and a substantial reduction in net loss for the nine months ended September 30, 2025, driven by YCANTH sales and collaboration milestones, despite ongoing liquidity concerns.

Summary

• Total revenue for the nine months ended September 30, 2025, increased to $30.485 million, up from $7.222 million in the same period of 2024.
• Product revenue, net, grew to $11.563 million for the nine months ended September 30, 2025, compared to $6.259 million in the prior year.
• License and collaboration revenue surged to $18.922 million for the nine months ended September 30, 2025, primarily due to $18.0 million in milestone payments from Torii.
• Net loss significantly decreased to $(9.812) million for the nine months ended September 30, 2025, a substantial improvement from $(60.377) million in the prior year.
• Cash and cash equivalents stood at $21.097 million as of September 30, 2025, down from $46.329 million at December 31, 2024.
• The company reported an accumulated deficit of $316.839 million as of September 30, 2025.
• Cash used in operating activities improved to $(13.036) million for the nine months ended September 30, 2025, compared to $(44.863) million in the prior year.
• YCANTH (VP-102) received regulatory approval in Japan (as TO-208) for molluscum contagiosum in September 2025, triggering a $10.0 million milestone payment.
• The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency provided positive feedback supporting a Marketing Authorization Application for YCANTH (VP-102) for molluscum contagiosum in the EU.
• The global Phase 3 program for YCANTH (VP-102) in common warts, in partnership with Torii, is expected to dose its first patient in the United States in the fourth quarter of 2025.
• VP-315, an oncolytic peptide-based injectable therapy for basal cell carcinoma (BCC), presented additional positive data at the SITC 40th Annual Meeting in November 2025, and received FDA end-of-Phase 2 feedback supporting an efficient Phase 3 program.
• A 1-for-10 reverse stock split was effected on July 24, 2025.

Sentiment

Score: 6

Explanation: The company shows strong operational improvements with significant revenue growth and reduced net losses, coupled with positive pipeline developments (Japan approval, EU feedback, VP-315 progress). However, the explicit 'going concern' doubt and the ongoing need for substantial additional capital introduce significant financial risk, balancing the positive operational momentum.

Positives

• Total revenue increased by over 322% to $30.485 million for the nine months ended September 30, 2025, compared to $7.222 million in the prior year.
• Net loss significantly reduced by approximately 83.7% to $(9.812) million for the nine months ended September 30, 2025, from $(60.377) million in the prior year.
• Operating cash outflow improved substantially to $(13.036) million for the nine months ended September 30, 2025, from $(44.863) million in the prior year.
• Received $18.0 million in milestone payments from Torii for the nine months ended September 30, 2025, including $10.0 million for YCANTH (TO-208) regulatory approval in Japan.
• YCANTH (VP-102) received positive feedback from the European Medicines Agency's CHMP, supporting a Marketing Authorization Application for molluscum contagiosum in the EU.
• VP-315 showed promising data at the SITC 40th Annual Meeting, indicating a robust local immune response and potential abscopal-like effect, with FDA end-of-Phase 2 feedback supporting an efficient Phase 3 program.
• The company expects to launch YCANTH Rx, a non-dispensing pharmacy, in Q4 2025 to streamline provider experience.

Negatives

• The company has an accumulated deficit of $316.839 million as of September 30, 2025, indicating historical and ongoing losses.
• Cash and cash equivalents decreased to $21.097 million as of September 30, 2025, from $46.329 million at December 31, 2024.
• Substantial doubt exists regarding the company's ability to continue as a going concern within one year due to operating losses, cash outflows, and debt obligations.
• The company is obligated to make monthly principal payments on its $50.0 million loan facility from OrbiMed, which began in January 2025, due to not meeting a specified net revenue target.
• The company's quarterly and annual financial statements are subject to a 'going concern' qualification, although waivers have been obtained for certain periods, future waivers are not assured.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern within one year due to ongoing operating losses and cash outflows.
• Inability to obtain additional funding through equity offerings, debt financing, collaborations, strategic alliances, or licensing arrangements could force delays or elimination of commercialization and development programs.
• The company is subject to 'baby shelf rules,' limiting the amount of funds that can be raised through primary public offerings using its Form S-3 registration statement to one-third of the aggregate market value of non-affiliate common stock until the public float exceeds $75.0 million.
• Failure to obtain future waivers for the 'going concern' qualification in financial statements or to meet the $10.0 million liquidity covenant could result in default under the Credit Agreement, leading to accelerated obligations and additional interest.
• Clinical trials for product candidates are time-consuming, expensive, and uncertain, with no guarantee of regulatory approval or commercial success.
• The reverse stock split may adversely affect the liquidity of common stock and could increase the cost of selling odd lots for stockholders.
• Ongoing putative class action and stockholder derivative lawsuits allege violations of federal securities laws and breaches of fiduciary duties, which, if successful, could materially affect the company's financial position.

Future Outlook

The company expects to launch YCANTH Rx, a non-dispensing pharmacy, in the fourth quarter of 2025 to streamline the provider experience. The field sales force is planned to expand to 50 employee sales representatives in 2026. The global Phase 3 program for YCANTH (VP-102) in common warts is expected to dose its first patient in the United States in the fourth quarter of 2025. For VP-315, the company is evaluating costs and logistics for the initiation of its Phase 3 program, supported by positive FDA end-of-Phase 2 feedback. The company is actively exploring non-dilutive strategic partnerships to fund the development and commercialization of YCANTH (VP-102) in additional geographic regions outside the United States and Japan, as well as for VP-315.

Management Comments

• We expect to launch YCANTH Rx, a non-dispensing pharmacy, in the fourth quarter of 2025 to streamline and simplify the provider experience.
• We expect to expand the field sales force to 50 employee sales representatives in 2026.
• We expect to dose the first patient in the global Phase 3 program for YCANTH (VP-102) in common warts in the United States in the fourth quarter of 2025.
• We believe the recent VP-315 data, coupled with the EOP2 regulatory feedback, further support the clinical efficacy and histologic clearance observed in the Phase 2 BCC trial and help inform next steps for the advancement of the program into Phase 3 clinical trials.
• This clarity also provides an opportunity for us to explore non-dilutive strategic partnerships to help fund the development and commercialization of VP-315.

Industry Context

Verrica Pharmaceuticals operates in the dermatology therapeutics industry, focusing on clinician-administered therapies for skin diseases with high unmet needs, such as molluscum contagiosum and common warts. The company is also developing an oncolytic peptide-based injectable therapy for dermatological oncologic conditions like basal cell carcinoma. The positive regulatory feedback for YCANTH in the EU and the progress of VP-315's clinical development indicate a strategic focus on expanding market reach and pipeline diversification within specialized dermatology and oncology segments. The pursuit of non-dilutive partnerships aligns with a common industry trend for smaller biopharma companies to leverage external funding and expertise for late-stage development and commercialization.

Legal Proceedings

• A putative class action complaint (Gorlamari v. Verrica Pharmaceuticals Inc., et al.) alleges violations of federal securities laws related to manufacturing deficiencies and regulatory approval prospects for YCANTH (VP-102). Claims against the company and one individual defendant were sufficiently pled.
• Stockholder derivative lawsuits (Ivan S. Cohen, Paul Cannon, Joseph Bonaccorso) were filed with similar factual allegations, naming the company as a nominal defendant. The Cohen and Cannon actions have been consolidated and stayed, while the Bonaccorso action was voluntarily dismissed.

Related Party Transactions

• The Chief Executive Officer, Jayson Rieger, and Chief Operating Officer, David Zawitz, are former employees of, and current consultants to, PBM Capital Group, LLC, an entity controlled by Paul B. Manning, a significant investor of the company.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings, but also benefit from improved financial performance and pipeline progress. The reverse stock split may affect trading liquidity.
• Employees: Sales force expansion planned for 2026, indicating growth in commercial operations.
• Customers: Launch of YCANTH Rx aims to streamline the prescription process, potentially improving access and experience.
• Creditors (OrbiMed): Principal payments on the loan facility have commenced, and compliance with liquidity covenants is critical to avoid default.
• Patients: Continued development of YCANTH for common warts and VP-315 for BCC offers potential new treatment options.

Next Steps

• Launch YCANTH Rx, a non-dispensing pharmacy, in Q4 2025.
• Expand the field sales force to 50 employee sales representatives in 2026.
• Dose the first patient in the global Phase 3 program for YCANTH (VP-102) in common warts in the United States in Q4 2025.
• Initiate a manufacturing transfer to Torii for YCANTH (TO-208) applicators for Japan, expected to take several years.
• Evaluate cost and logistics for the initiation of the Phase 3 program for VP-315.
• Explore non-dilutive strategic partnerships to fund development and commercialization for YCANTH (VP-102) outside the US and Japan, and for VP-315.

Key Dates

Recommendation

While Verrica Pharmaceuticals has demonstrated significant operational improvements, including substantial revenue growth from YCANTH sales and collaboration milestones, and a notable reduction in net loss, the explicit 'going concern' qualification and the ongoing need for significant capital raise present material financial risks. The positive pipeline developments, such as YCANTH's Japan approval and EU feedback, and VP-315's clinical progress, offer future upside. However, the uncertainty surrounding future financing and the potential for debt default warrant a cautious 'hold' stance. Investors should monitor the company's ability to secure additional funding and resolve its going concern issues before considering a more aggressive position.

Keywords

Verrica Pharmaceuticals, VRCA, YCANTH, VP-102, molluscum contagiosum, common warts, VP-315, basal cell carcinoma, dermatology therapeutics, SEC filing, 10-Q, financial results, clinical trials, FDA approval, Torii collaboration, biopharma, going concern